Results 11 to 20 of about 45,512 (293)

Inhibition and degradation of NRAS with a pan-NRAS monobody [PDF]

Oncogene
AbstractThe RAS family GTPases are the most frequently mutated oncogene family in human cancers. Activating mutations in either of the three RAS isoforms (HRAS, KRAS, or NRAS) are found in nearly 20% of all human tumors with NRAS mutated in ~25% of melanomas.
Michael Whaby, Gayatri Ketavarapu, Akiko Koide, Megan Mazzei, Mubashir Mintoo, Eliezra Glasser, Unnatiben Patel, Cecile Nasarre, Matthew J. Sale, Frank McCormick, Shohei Koide, John P. O’Bryan   +11 more
openaire   +5 more sources

Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies

Communications Medicine
Background Melanoma is an aggressive form of skin cancer, and patients with NRAS-mutant melanoma face limited treatment options due to the lack of direct NRAS inhibitors.
Valentin Feichtenschlager, Yixuan James Zheng, Tiange Qu, Dasha Hohlova, Ciara Callanan, Linan Chen, Christopher Chen, Wilson Ho, Albert Lee, Yeonjoo Hwang, Arowyn Courtright, Thy Nguyen, Olivia Marsicovetere, Denise P. Muñoz, Klemens Rappersberger, Jean-Philippe Coppe, Susana Ortiz-Urda   +16 more
doaj   +2 more sources

Identification of NRAS Downstream Genes with CRISPR Activation Screening

Biology, 2022
Mutations in NRAS constitutively activate cell proliferation signaling in malignant neoplasms, such as leukemia and melanoma, and the clarification of comprehensive downstream genes of NRAS might lead to the control of cell-proliferative signals of NRAS ...
Akiya Tatsumi, Haruka Hirakochi, Satomi Inoue, Yosuke Tanaka, Hidehiro Furuno, Masumi Ikeda, Sachiko Ishibashi, Towako Taguchi, Kouhei Yamamoto, Iichiroh Onishi, Zohar Sachs, David A. Largaespada, Masanobu Kitagawa, Morito Kurata   +13 more
doaj   +2 more sources

NRAS destines tumor cells to the lungs [PDF]

EMBO Molecular Medicine, 2017
The lungs are frequently affected by cancer metastasis. Although NRAS mutations have been associated with metastatic potential, their exact role in lung homing is incompletely understood.
Anastasios D Giannou, Antonia Marazioti, Nikolaos I Kanellakis, Ioanna Giopanou, Ioannis Lilis, Dimitra E Zazara, Giannoula Ntaliarda, Danai Kati, Vasileios Armenis, Georgia A Giotopoulou, Anthi C Krontira, Marina Lianou, Theodora Agalioti, Malamati Vreka, Maria Papageorgopoulou, Sotirios Fouzas, Dimitrios Kardamakis, Ioannis Psallidas, Magda Spella, Georgios T Stathopoulos   +19 more
doaj   +2 more sources

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. [PDF]

PLoS ONE, 2016
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of ...
Michael K Kiessling, Alessandra Curioni-Fontecedro, Panagiotis Samaras, Silvia Lang, Michael Scharl, Adriano Aguzzi, Derek A Oldrige, John M Maris, Gerhard Rogler   +8 more
doaj   +3 more sources

Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

Nature Communications
Activating mutations in NRAS account for 15–20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K,
Yalei Wen, Hui Wang, Xiao Yang, Yingjie Zhu, Mei Li, Xiuqing Ma, Lei Huang, Rui Wan, Caishi Zhang, Shengrong Li, Hongling Jia, Qin Guo, Xiaoyun Lu, Zhengqiu Li, Xiangchun Shen, Qiushi Zhang, Lu Si, Chengqian Yin, Tongzheng Liu   +18 more
doaj   +2 more sources

Enhancement of the leptomeninges in a young man. [PDF]

Brain Pathol
Brain Pathology, EarlyView.
Ray J, Alberawi M, Bauer A, Fung KM, Horta ES, Robinson LJ.   +5 more
europepmc   +2 more sources

Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma Patients

Acta Medica Bulgarica, 2021
Introduction: Thyroid carcinoma is the most common endocrine cancer. Some somatic mutations in genes (BRAF, NRAS and TERT) involved in key signaling pathways and genome stability have been recently identified to play an important role in its development.
Vidinov K., Dodova R., Mitev P., Mitkova A., Dimitrova I., Shinkov A., Ivanova R., Mitev V., Kaneva R.   +8 more
doaj   +1 more source

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma [PDF]

, 2021
Inhibidor de MEK; Mutació NRAS; Melanoma metastàticInhibidor de MEK; Mutación NRAS; Melanoma metastásicoMEK inhibitor; NRAS mutation; Metastatic melanomaMelanoma is the deadliest cutaneous cancer.
Garcia-Alvarez, Alejandro, Muñoz Couselo, Eva, Ortiz Velez, Carolina   +2 more
core   +1 more source

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study

Türk Patoloji Dergisi, 2023
Objective: Primary anorectal melanomas (AMs) are uncommon neoplasms with aggressive behavior. Molecular profile and clinicopathologic features of AMs are still not well established.
Orhun Cig TASKIN, Sule OZTURK SARI, Ismail YILMAZ, Ozge HURDOGAN, Metin KESKIN, Nesimi BUYUKBABANI, Mine GULLUOGLU   +6 more
doaj   +1 more source